Company news

Innate Pharma SA news in 2026

Innate Pharma SA's news releases, calls and decks from 2026, newest first.

View company

Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027

October 27, 2026

Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference

October 21, 2026

Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update

October 20, 2026

Innate Pharma Reports First Half 2026 Business Update and Financial Results

September 17, 2026

Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions

September 16, 2026

Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update

September 10, 2026

Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 2, 2026

Innate Pharma Announces Pricing of €30 million Offering of Ordinary Shares

August 14, 2026

Innate Pharma Announces Proposed Offering of Ordinary Shares

August 13, 2026

Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer

August 10, 2026

Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma

August 10, 2026

Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference

July 23, 2026

Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)

July 21, 2026

Outcome of Innate Pharma’s 2026 Annual General Meeting

May 22, 2026

Innate Pharma to participate in the Jefferies Global Healthcare Conference

May 19, 2026

Innate Pharma Reports First Quarter 2026 Business Update and Financial Results

May 13, 2026

Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026

May 12, 2026

Innate Pharma Announces Conference Call and Webcast for Q1 2026 Business Update

May 6, 2026

Innate Pharma to Participate in the D. Boral Capital Global Conference

April 23, 2026

Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026

April 17, 2026

Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026

April 13, 2026

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 21, 2026

April 13, 2026

Innate Pharma to Present at the AACR 2026 Oncology Industry Partnering Event

April 8, 2026

Innate Pharma to Participate in the Kempen Life Sciences Conference

April 3, 2026

Innate Pharma Files Its 2025 Universal Registration Document (Document D’enregistrement Universel) and 2025 Form 20-f Annual Report

April 2, 2026

Innate Pharma Reports Full Year 2025 Financial Results and Business Update

March 26, 2026

Innate Pharma Announces Conference Call and Webcast for Full Year 2025 Financial Results

March 19, 2026

Number of Shares and Voting Rights of Innate Pharma as of February 19, 2026

February 19, 2026

Innate Pharma to Participate in the Leerink Partners Global Healthcare Conference

February 18, 2026

Number of Shares and Voting Rights of Innate Pharma as of December 31, 2025

January 7, 2026

Calls in 2026

Decks in 2026